Total Payments
$8,091
2024 Payments
$667.67
Companies
44
Transactions
443
Medicare Patients
685
Medicare Billing
$108,094
Payment Breakdown by Category
Food & Beverage$7,804 (96.4%)
Education$218.13 (2.7%)
Other$69.51 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,804 | 424 | 96.4% |
| Education | $218.13 | 16 | 2.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $69.51 | 3 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $1,134 | 71 | $0 (2024) |
| UCB, Inc. | $1,037 | 53 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $996.42 | 74 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $728.53 | 44 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $444.89 | 25 | $0 (2021) |
| Neurocrine Biosciences, Inc. | $442.64 | 19 | $0 (2024) |
| EMD Serono, Inc. | $356.05 | 17 | $0 (2024) |
| US WorldMeds, LLC | $218.61 | 12 | $0 (2020) |
| Adamas Pharmaceuticals, Inc. | $218.56 | 13 | $0 (2021) |
| Lilly USA, LLC | $153.91 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $667.67 | 33 | Novartis Pharmaceuticals Corporation ($147.54) |
| 2023 | $501.32 | 26 | Novartis Pharmaceuticals Corporation ($101.51) |
| 2022 | $861.86 | 42 | Novartis Pharmaceuticals Corporation ($181.81) |
| 2021 | $886.00 | 48 | Biogen, Inc. ($218.16) |
| 2020 | $1,246 | 66 | UCB, Inc. ($193.18) |
| 2019 | $1,297 | 75 | Biogen, Inc. ($205.41) |
| 2018 | $1,485 | 81 | UCB, Inc. ($315.90) |
| 2017 | $1,146 | 72 | UCB, Inc. ($220.41) |
All Payment Transactions
443 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $19.55 | General |
| 12/04/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: Neuroscience | ||||||
| 11/20/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $13.89 | General |
| Category: NEUROLOGY | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $26.38 | General |
| Category: Neurology | ||||||
| 10/16/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Neurology | ||||||
| 10/10/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: Neuropsychiatry | ||||||
| 09/25/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 09/18/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: Neuroscience | ||||||
| 09/11/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $13.60 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/04/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $16.06 | General |
| Category: NEUROLOGY | ||||||
| 08/14/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: Neuropsychiatry | ||||||
| 08/07/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $21.31 | General |
| Category: Neurology | ||||||
| 07/10/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: Neurology | ||||||
| 06/20/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $16.06 | General |
| Category: NEUROLOGY | ||||||
| 06/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Neuropsychiatry | ||||||
| 06/05/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: Rare Disease | ||||||
| 05/29/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $25.73 | General |
| Category: Neurology | ||||||
| 05/08/2024 | ACADIA Pharmaceuticals Inc | DAYBUE (Drug) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: RETT SYNDROME | ||||||
| 05/01/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: Neurology | ||||||
| 04/19/2024 | Amgen Inc. | UPLIZNA (Biological) | Education | In-kind items and services | $13.11 | General |
| Category: Inflammation/Rare Disease | ||||||
| 04/17/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: Neurology | ||||||
| 04/10/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 03/20/2024 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: Neuroscience | ||||||
| 03/13/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: Neurology | ||||||
| 03/07/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: PAIN | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 92 | 116 | $28,500 | $16,737 |
| 2022 | 6 | 153 | 171 | $44,252 | $25,985 |
| 2021 | 9 | 232 | 271 | $71,237 | $41,848 |
| 2020 | 7 | 208 | 238 | $52,962 | $23,524 |
Total Patients
685
Total Services
796
Medicare Billing
$108,094
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 53 | 66 | $16,500 | $9,927 | 60.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $7,488 | $4,699 | 62.8% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 13 | 24 | $4,512 | $2,110 | 46.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 48 | 48 | $13,824 | $8,891 | 64.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 49 | 55 | $13,750 | $8,427 | 61.3% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2022 | 14 | 14 | $5,628 | $3,201 | 56.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 15 | 25 | $4,700 | $2,322 | 49.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 16 | 17 | $4,250 | $1,912 | 45.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 12 | $2,100 | $1,231 | 58.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 46 | 51 | $12,750 | $8,103 | 63.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 40 | 40 | $11,520 | $7,470 | 64.8% |
| 95819 | Measurement and recording of brain wave (eeg) activity, awake and asleep | Office | 2021 | 16 | 16 | $9,280 | $6,896 | 74.3% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 21 | 44 | $8,272 | $4,160 | 50.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 27 | 27 | $7,560 | $3,739 | 49.5% |
| 95912 | Nerve transmission studies, 11-12 studies | Office | 2021 | 15 | 15 | $6,030 | $3,578 | 59.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 22 | 29 | $7,250 | $3,338 | 46.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 20 | 21 | $3,675 | $2,413 | 65.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 25 | 28 | $4,900 | $2,151 | 43.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 55 | 62 | $15,500 | $6,776 | 43.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 24 | 24 | $6,912 | $3,736 | 54.0% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2020 | 20 | 39 | $7,520 | $3,452 | 45.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 42 | 43 | $7,525 | $3,378 | 44.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 26 | 28 | $7,000 | $2,705 | 38.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 30 | 31 | $5,425 | $2,075 | 38.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 11 | 11 | $3,080 | $1,402 | 45.5% |
About Dr. Majid Molaie, M.D
Dr. Majid Molaie, M.D is a Specialist healthcare provider based in Rancho Palos Verdes, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356411904.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Majid Molaie, M.D has received a total of $8,091 in payments from pharmaceutical and medical device companies, with $667.67 received in 2024. These payments were reported across 443 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($7,804).
As a Medicare-enrolled provider, Molaie has provided services to 685 Medicare beneficiaries, totaling 796 services with total Medicare billing of $108,094. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Rancho Palos Verdes, CA
- Active Since 11/09/2006
- Last Updated 01/14/2010
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1356411904
Products in Payments
- NUPLAZID (Drug) $962.38
- Briviact (Drug) $621.03
- KESIMPTA (Drug) $542.93
- TYSABRI (Biological) $500.49
- INGREZZA (Drug) $442.64
- Vimpat (Drug) $370.07
- VUMERITY (Drug) $366.21
- GOCOVRI (Drug) $290.44
- TROKENDI XR (Drug) $230.05
- TECFIDERA (Drug) $212.94
- NUEDEXTA (Drug) $159.28
- Wakix (Drug) $137.78
- AUBAGIO (Drug) $134.61
- ACTIVA (Device) $125.65
- Aimovig (Biological) $125.29
- OXTELLAR XR (Drug) $116.00
- MYOBLOC (Biological) $91.03
- VYEPTI (Biological) $88.65
- Xadago (Drug) $83.30
- NOURIANZ (Drug) $82.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.